Table 1.
Baseline characteristics of all patients and the subset of patients treated to the combined hypercellular/hyperperfused tumor
| All Patients (%) | Patients treated with targeting of hypercellular/hyperperfused tumor (%) | |
|---|---|---|
| Count | ||
| N | 23 | 13 |
| Age | ||
| Median (Interquartile range) | 61 (56, 66) | 59 (56, 65) |
| Gender | ||
| Female | 7 (30) | 5 (39) |
| Male | 16 (70) | 8 (61) |
| Race | ||
| White | 21 (92) | 12 (92) |
| Black or African American | 1 (4) | 1 (8) |
| Asian | 1 (4) | 0 (0) |
| ECOG* Performance Status | ||
| 0 | 5 (22) | 3 (23) |
| 1 | 17 (74) | 9 (69) |
| 2 | 1 (4) | 1 (8) |
| Baseline Neurologic Status† | ||
| Normal | 9 (39) | 5 (38) |
| Mild | 12 (52) | 7 (54) |
| Moderate | 2 (9) | 1 (8) |
| Severe | 0 (0) | 0 (0) |
| Extent of Surgery | ||
| Gross total resection | 13 (57) | 8 (62) |
| Subtotal resection | 7 (30) | 3 (23) |
| Biopsy | 3 (13) | 2 (15) |
| MGMT‡ Methylation Status | ||
| Positive | 5 (22) | 3 (23) |
| Negative | 18 (78) | 10 (77) |
| IDH€ Mutation Status | ||
| Mutant | 0 (0) | 0 (0) |
| Wild-Type | 22 (96) | 13 (100) |
| Unknown | 1 (4) | 0 (0) |
| Tumor laterality | ||
| Right | 8 (35) | 5 (38) |
| Left | 15 (65) | 8 (62) |
| Tumor location | ||
| Frontal | 11 (48) | 7 (54) |
| Temporal | 7 (30) | 3 (23) |
| Parietal | 2 (9) | 2 (15) |
| >1 lobe | 3 (13) | 1 (8) |
| Handedness | ||
| Right | 20 (87) | 11 (85) |
| Left | 3 (13) | 2 (15) |
| Education | ||
| ≤ 12 years | 4 (17) | 1 (8) |
| >12 years | 19 (83) | 12 (92) |
*
ECOG = Eastern Cooperative Oncology Group;
†
Using the Neurologic Assessment in Neuro-Oncology (NANO) Scale, defined as at least 1 neurologic function deficit of the specified severity in at least 1 domain;
‡
MGMT = O6-methylguanine-DNA methyltransferase; €IDH = Isocitrate dehydrogenase